The content on this site is intended for healthcare professionals only
Dr Han speaks with ecancertv at SABCS 2016 about the outcomes from a trial of added velaparib to chemotherapy for BRCA1/2 mutant metastatic breast cancers.
Compared to carboplatin and paclitaxel, she describes the addition of velaparib as extending progression free survival, though not to a statistically significant extent, with no additional toxicity.
These results were first presented at a press conference session, with coverage available here.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert round up July 28th to August 3rd, 2023
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Overview of the management of HER2-low breast cancer patients
